These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

863 related items for PubMed ID: 11802586

  • 1. The role of databases in drug postmarketing surveillance.
    Rodriguez EM, Staffa JA, Graham DJ.
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [Abstract] [Full Text] [Related]

  • 2. Automated support for pharmacovigilance: a proposed system.
    Bright RA, Nelson RC.
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [Abstract] [Full Text] [Related]

  • 3. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, Avigan M.
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [Abstract] [Full Text] [Related]

  • 4. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K.
    Ann Clin Psychiatry; 2008 Nov; 20(1):21-31. PubMed ID: 18297583
    [Abstract] [Full Text] [Related]

  • 5. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK, Swartz L.
    Arch Intern Med; 2005 Jun 27; 165(12):1363-9. PubMed ID: 15983284
    [Abstract] [Full Text] [Related]

  • 6. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA.
    Food Drug Law J; 2007 Jun 27; 62(3):513-28. PubMed ID: 17915393
    [No Abstract] [Full Text] [Related]

  • 7. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C.
    Pharmacoepidemiol Drug Saf; 2002 Sep 27; 11(6):439-46. PubMed ID: 12426927
    [Abstract] [Full Text] [Related]

  • 8. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
    Hochberg AM, Hauben M.
    Clin Pharmacol Ther; 2009 Jun 27; 85(6):600-6. PubMed ID: 19322165
    [Abstract] [Full Text] [Related]

  • 9. Drug safety. Gaps in the safety net.
    Couzin J.
    Science; 2005 Jan 14; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract] [Full Text] [Related]

  • 10. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P, Sarma DN, Low Dog T, Barrett ML, Chavez ML, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI.
    Pharmacoepidemiol Drug Saf; 2008 Oct 14; 17(10):962-70. PubMed ID: 18613260
    [Abstract] [Full Text] [Related]

  • 11. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP, Salas M, Delzell E.
    J Clin Pharmacol; 2007 Sep 14; 47(9):1074-86. PubMed ID: 17766697
    [Abstract] [Full Text] [Related]

  • 12. MEDWatch: the new FDA medical products reporting program.
    Kessler DA.
    Am J Hosp Pharm; 1993 Jun 14; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract] [Full Text] [Related]

  • 13. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
    Matthews EJ, Frid AA.
    Regul Toxicol Pharmacol; 2010 Apr 14; 56(3):247-75. PubMed ID: 19932726
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW.
    Arch Intern Med; 2007 May 28; 167(10):1041-9. PubMed ID: 17533207
    [Abstract] [Full Text] [Related]

  • 15. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M, Vegni F, Reich L, Younus M.
    Eur J Gastroenterol Hepatol; 2007 Nov 28; 19(11):934-41. PubMed ID: 18049161
    [Abstract] [Full Text] [Related]

  • 16. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F.
    Expert Rev Vaccines; 2005 Aug 28; 4(4):445-8. PubMed ID: 16117700
    [No Abstract] [Full Text] [Related]

  • 17. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT, Staffa JA, Parks M, Green L.
    Pharmacoepidemiol Drug Saf; 2004 Jul 28; 13(7):417-26. PubMed ID: 15269925
    [Abstract] [Full Text] [Related]

  • 18. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G.
    Pharmacoepidemiol Drug Saf; 2012 Jun 28; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [Abstract] [Full Text] [Related]

  • 19. MedWatch. FDA's 'heads up' on medical product safety.
    Henkel J.
    FDA Consum; 1998 Jun 28; 32(6):10-2, 15. PubMed ID: 9854445
    [No Abstract] [Full Text] [Related]

  • 20. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M, Reich L, Gerrits CM.
    Pharmacoepidemiol Drug Saf; 2006 Nov 28; 15(11):775-83. PubMed ID: 16804951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.